Cardiovascular responses to the tyrosine kinase inhibitor imatinib were investigated in the
rat. Intravenous injections of 0.3–30 mg/kg imatinib produced small decreases in pulmonary …

Premature ejaculation (PE) is the most prevalent male sexual dysfunction. This is associated
with negative personal and interpersonal psychological outcomes. The pharmacologic …

Background Erectile dysfunction (ED) is a major health issue in aged populations, and
neurogenic ED is particularly difficult to treat. Novel therapeutic approaches are needed for …

Lung cancer is the leading cause of mortality due to tumor malignancy worldwide. In recent
years, the treatment of lung cancer with chemotherapy has demonstrated notable resistance …

Abstract Background Tyrosine kinase inhibitors (TKIs) inhibit the platelet derived growth
factor receptor (PDGFR) and gain increasing significance in the therapy of proliferative …

The present study aimed to investigate the effect of anlotinib (AL3818) on pharmacokinetics
of cytochrome P450 (CYP) enzymes (CYP1A2, CYP2C6, CYP2D1, CYP2D2, and …

Objective To examine the effects of mirabegron, a selective β3‐adrenoceptor agonist that
has recently been approved for the treatment of overactive bladder (OAB), on erectile …

Background Recently, the IMPRES study revealed that systemic imatinib improves exercise
capacity in patients with advanced pulmonary arterial hypertension. Imatinib blocks the …

Hepatocellular carcinoma (HCC) treatment remains lack of effective chemotherapeutic
drugs, therefore, discovering novel anti-HCC drugs is a very attractive and urgent task. In …

Abstract Purpose of Review Targeted therapy for genitourinary cancer is being used at an
increasing rate. These medications show great survival benefit but are relatively lacking in …